Crossing these Jnk1 LoxP/LoxP / Jnk2 -/- mice with Alb-Cre mice produced Jnk hepa (Cubero et al., 2016)
Discontinuation rates were higher than in Phase 2 trials - 18.2% at the 12mg dose versus 4% with placebo
If the agency agrees, that is the key technical hurdle cleared
In addition, approximately 1 in 3 participants (31.6%) who received cagrilintide achieved a weight loss 15%, compared to approximately 1 in 20 participants (4.7%) who received placebo
BHRC BLOG How AOD-9604 Supports Joint Health and Cartilage Repair Joint health deterioration affects millions of people worldwide, limiting mobility and reducing quality of life
Bring your weight log, notes on appetite and energy, dietary records if possible, and any changes in stress, sleep, or exercise